Vijay Modur

1.3k total citations
25 papers, 842 citations indexed

About

Vijay Modur is a scholar working on Molecular Biology, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Vijay Modur has authored 25 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Physiology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Vijay Modur's work include Lysosomal Storage Disorders Research (5 papers), Genetic and Kidney Cyst Diseases (4 papers) and Alzheimer's disease research and treatments (3 papers). Vijay Modur is often cited by papers focused on Lysosomal Storage Disorders Research (5 papers), Genetic and Kidney Cyst Diseases (4 papers) and Alzheimer's disease research and treatments (3 papers). Vijay Modur collaborates with scholars based in United States, United Kingdom and France. Vijay Modur's co-authors include Omar Laterza, Jack H. Ladenson, Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Jitka V. Olander, Jerald P. Radich, Jaspal Kaeda, Jin‐Moo Lee and John M. Goldman and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Vijay Modur

24 papers receiving 820 citations

Peers

Countries citing papers authored by Vijay Modur

Since Specialization

Citations

This map shows the geographic impact of Vijay Modur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vijay Modur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vijay Modur more than expected).

Fields of papers citing papers by Vijay Modur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vijay Modur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vijay Modur. The network helps show where Vijay Modur may publish in the future.

Co-authorship network of co-authors of Vijay Modur

This figure shows the co-authorship network connecting the top 25 collaborators of Vijay Modur. A scholar is included among the top collaborators of Vijay Modur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vijay Modur. Vijay Modur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 1591: Mechanisms of BPM31510-induced cell death in cancer: lipid peroxidation and apoptosis pathways 2025 ·Cancer Research ·Ali Khojasteh, Michael A. Kiebish, (unknown), Sylwia A. Stopka, Juan J. Aristizabal‐Henao, Seema Nagpal, (unknown), Stéphane Gesta, Niven R. Narain, Vijay Modur, Lawrence D. Recht	1
2	499TiP A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy 2024 ·Annals of Oncology ·(unknown), S. Bertrand, (unknown), (unknown), (unknown), Brian Berman, Vivek K. Vishnudas, Michael A. Kiebish, Stéphane Gesta, (unknown), Niven R. Narain, (unknown), Vijay Modur, Seema Nagpal	0
3	Predictive multi-omics analysis of BPM31510 in combination with gemcitabine in a phase 2 study of advanced pancreatic ductal adenocarcinoma (PDAC). 2024 ·Journal of Clinical Oncology ·Madappa N. Kundranda, Can Bruce, Elder Granger, Brian Berman, Vijay Modur, Rangaprasad Sarangarajan, (unknown), Lynne A. Bui, James Strauss, Angela Alistar, Sant P. Chawla, Roopinder Gillmore, Manuel Hidalgo, (unknown), (unknown), (unknown), Michael A. Kiebish, Niven R. Narain, David Propper	1
4	Novel read through agent: ZKN-0013 demonstrates efficacy in APCmin model of familial adenomatous polyposis 2023 ·Journal of Molecular Medicine ·Martin R. Graf, (unknown), Esteban Terzo, (unknown), Shuhao Shi, Megan K. Cox, Roger B. Clark, Vijay Modur, Vasudeo Badarinarayana	4
5	A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer 2023 ·Cancer Research Communications ·Esteban Terzo, (unknown), (unknown), (unknown), (unknown), (unknown), Anupama Reddy, Shuhao Shi, (unknown), Roger B. Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana	2
6	Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial 2022 ·American Journal of Kidney Diseases ·Ronald T. Gansevoort, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B. Chapman, Shigeo Horie, Bertrand Knebelmann, Michal Mrug, Albert Ong, York Pei, Vicente E. Torres, Vijay Modur, (unknown), Ronald D. Perrone	12
7	The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD 2022 ·Kidney Medicine ·Ronald D. Perrone, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B. Chapman, Shigeo Horie, Bertrand Knebelmann, Michal Mrug, Albert Ong, York Pei, Vicente E. Torres, Vijay Modur, Ronald T. Gansevoort	7
8	Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study 2022 ·Molecular Genetics and Metabolism ·Patrick Deegan, Özlem Göker-Alpan, Tarekegn Geberhiwot, Robert J. Hopkin, Elena Lukina, Anna Tylki‐Szymańska, Atef Zaher, (unknown), Sebastiaan J.M. Gaemers, Vijay Modur, Beth L. Thurberg, Jyoti Sharma, Behzad Najafian, Michael Mauer, Pronabesh DasMahapatra, William R. Wilcox, Dominique P. Germain	33
9	Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease 2021 ·Molecular Genetics and Metabolism Reports ·Alaa Hamed, Pronabesh DasMahapatra, (unknown), Chad Gwaltney, (unknown), Daniel Serrano, Vijay Modur, Juan Politei	6
10	Glycosphingolipid metabolism and polycystic kidney disease 2020 ·Cellular Signalling ·Thomas A. Natoli, Vijay Modur, Oxana Ibraghimov‐Beskrovnaya	20
11	Correction of cilia structure and function alleviates multi-organ pathology in Bardet–Biedl syndrome mice 2020 ·Human Molecular Genetics ·Hervé Husson, Nikolay O. Bukanov, Sarah Moreno, (unknown), Brenda Richards, Cheng Zhu, Tyler Picariello, Hye Jung Park, Bing Wang, Thomas A. Natoli, Laurie A. Smith, Stefano Zanotti, Ryan J. Russo, Stephen F. Madden, K. Klinger, Vijay Modur, Oxana Ibraghimov‐Beskrovnaya	10
12	Biomarkers in Pharmaceutical Research 2015 ·Clinical Chemistry ·Xuemei Zhao, Vijay Modur, Leonidas N. Carayannopoulos, Omar Laterza	37
13	Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort 2015 ·Journal of Alzheimer s Disease ·Jeffrey L. Seeburger, Daniel Holder, Marc Combrinck, Catharine Joachim, Omar Laterza, Michael Tanen, Aimée Dallob, Derek L Chappell, Karen Snyder, (unknown), Adam Simon, Vijay Modur, William Z. Potter, Gordon Wilcock, Mary J. Savage, A. David Smith	62
14	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale 2013 ·Clinical Chemistry ·Helen White, John Hedges, Israel Bendit, Susan Branford, Dolors Colomer, Andreas Hochhaus, Timothy P. Hughes, Suzanne Kamel‐Reid, Dong‐Wook Kim, Vijay Modur, Martin Müller, Kátia Bórgia Barbosa Pagnano, Fabrizio Pane, Jerry Radich, Nicholas C.P. Cross, Emmanuel Labourier	33
15	Evidence-Based Laboratory Medicine in Oncology Drug Development: From Biomarkers to Diagnostics 2012 ·Clinical Chemistry ·Vijay Modur, Eric Hailman, J. Carl Barrett	7
16	Are Companion Diagnostics Useful? 2012 ·Clinical Chemistry ·J. Carl Barrett, Melanie M. Frigault, Simon J. Hollingsworth, Glenn A. Miller, Vijay Modur	7
17	BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment 2011 ·Clinical Cancer Research ·Andrew M. Stein, Dean Bottino, Vijay Modur, Susan Branford, Jaspal Kaeda, John M. Goldman, Timothy P. Hughes, Jerald P. Radich, Andreas Hochhaus	32
18	The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients 2008 ·Clinical Chemistry ·Jin‐Moo Lee, Kaj Blennow, Niels Andreasen, Omar Laterza, Vijay Modur, Jitka V. Olander, Feng Gao, (unknown), Jack H. Ladenson	93
19	Biomarkers of Tissue Injury 2008 ·Biomarkers in Medicine ·Omar Laterza, Vijay Modur, Jack H. Ladenson	11
20	Identification of Novel Brain Biomarkers 2006 ·Clinical Chemistry ·Omar Laterza, Vijay Modur, Dan L. Crimmins, Jitka V. Olander, Yvonne Landt, Jin‐Moo Lee, Jack H. Ladenson	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact